Related Experiment Video
Updated: Feb 19, 2026
06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
10.2K
Rifampicin Alleviates Atopic Dermatitis-Like Response in vivo and in vitro
Seung Hyun Kim1, Ki Man Lee1, Geum Seon Lee1
1Institute of Chronic Disease and College of Pharmacy, Sahmyook University, Seoul 01795, Republic of Korea.
Biomolecules & Therapeutics
|October 31, 2017
Summary
Rifampicin, an anti-tuberculosis drug, effectively reduced atopic dermatitis (AD) symptoms in mice by suppressing inflammatory responses and mast cell activation. This study suggests rifampicin
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a prevalent inflammatory skin condition.
- Inflammatory cells like macrophages and mast cells play a key role in AD pathogenesis.
- Rifampicin, primarily an anti-tuberculosis medication, exhibits anti-inflammatory and immunosuppressive properties.
Purpose of the Study:
- To investigate the therapeutic potential of rifampicin in treating atopic dermatitis (AD).
- To evaluate the effects of rifampicin on AD symptoms and underlying inflammatory mechanisms both in vivo and in vitro.
Main Methods:
- Atopic dermatitis was induced in NC/Nga mice using 2,4-dinitrochlorobenzene (DNCB).
- Mice were orally administered rifampicin, and clinical scores and scratching behavior were assessed.
- Serum levels of immunoglobulin E (IgE) and interleukin-4 (IL-4) were measured.
- In vitro studies involved stimulating human mast cell (HMC)-1 with compound 48/80 to assess rifampicin's effect on mediator release (β-hexosaminidase, histamine, TNF-α, PGD₂).
- Messenger RNA (mRNA) expression of cyclooxygenase 2 (COX-2) was analyzed in rifampicin-treated mast cells.
Main Results:
- Rifampicin treatment significantly alleviated AD severity scores and reduced scratching behavior in mice.
- Serum IgE and IL-4 levels were notably decreased in the rifampicin-treated group.
- Rifampicin inhibited the release of β-hexosaminidase and histamine from activated human mast cells.
- The drug suppressed the secretion of inflammatory mediators, including tumor necrosis factor-α (TNF-α) and prostaglandin D₂ (PGD₂).
- Rifampicin treatment led to a concentration-dependent reduction in cyclooxygenase 2 (COX-2) mRNA expression in mast cells.
Conclusions:
- Rifampicin demonstrates significant anti-atopic dermatitis activity.
- The therapeutic effects of rifampicin are attributed to the suppression of mast cell activation and inflammatory mediator release.
- Rifampicin holds promise as a potential therapeutic agent for atopic dermatitis.
